In Depth 22 Jul 2022
The coming of age story of RNAi technology
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two…
Silence Therapeutics
- Latest Posts
Best in Biotech 28 Dec 2020
A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …
News and Trends 26 Mar 2020
Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which…
More News! 19 Jul 2019
Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M
The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt…
ADVERTISEMENT
News and Trends 11 Dec 2018
UK Biotech Settles Lawsuit on the First RNAi Drug
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference…
In Depth 23 Jan 2018
Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?
Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back…
In Depth 19 Sep 2017
RNA as a Therapy: Reviewing the Future Generation of Therapeutics
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that…
News and Trends 15 Nov 2016
CRISPR meets RNAi: a whole new Targeted Therapy
Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and…
